
Aurinia Pharmaceuticals Inc: financial statements
Price
$15.18
November 18, 2026Market cap $2.0B
What Ploutos Investor adds for Aurinia Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 10 fiscal years, from 2016
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Most of the reported profit is a tax credit, not money earned from customers. We leave out the P/E and the earnings growth, which would not compare with a company that paid tax.
Financial statements
Each fiscal year's income statement, balance sheet and cash flow as the company filed them, and the latest quarters.
Click a line to see it on the chart.
Revenue
+27.0% a year over 2 years
| Line | 2023 | 2024 | 2025 | Average a year |
|---|---|---|---|---|
| Revenue | $176M | $235M | $283M | +27.0% |
| Cost of revenue | $14M | $28M | $33M | +51.9% |
| Gross profit | $161M | $207M | $250M | +24.5% |
| Operating income | -$92M | -$4.7M | $105M | |
| Net income | -$78M | $5.8M | $287M | |
| Earnings per share | -$0.54 | $0.04 | $2.07 | |
| Earnings per share, basic | -$0.54 | $0.04 | $2.14 | |
| Margins | ||||
| Gross margin | 91.9% | 88.0% | 88.5% | |
| Operating margin | -52.2% | -2.0% | 37.1% | |
| Net margin | -44.5% | 2.4% | 101.5% | |
Financial statements
AUPH's revenue, profits and cash flows from 2016 to 2022, 7 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
By segment
Revenue and operating income by business segment or by product, as the company itself reports them in each year's 10-K. Each year from the latest filing that carries it, so a segment renamed or re-cut shows in its current form.
- Product
- License Collaboration And Royalty Revenue
- 2023: Product $159M, License Collaboration And Royalty Revenue $17M
- 2024: Product $216M, License Collaboration And Royalty Revenue $19M
- 2025: Product $271M, License Collaboration And Royalty Revenue $12M
| Product | 2023 | 2024 | 2025 | Share 2025 |
|---|---|---|---|---|
| Product | $159M | $216M | $271M | 96% |
| License Collaboration And Royalty Revenue | $17M | $19M | $12M | 4.1% |
By segment
AUPH's revenue by product line from 2018 to 2022, 3 more fiscal years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 5 fiscal years.
From the XBRL of 11 of the company's annual reports to the SEC (ASC 280). Amounts in dollars.
Amounts are in dollars as the company filed them in its annual reports (10-K or 20-F). Those reporting in another currency are converted at each fiscal year-end rate. Shares and earnings per share are adjusted for splits.
Debt and obligations
What the company owes beyond the loans on its balance sheet, and when it pays, from the notes to its annual report: debt maturities, leases, pension plans, goodwill by segment, and how it gets to the tax it pays.
Leases
Dec 31, 2025Operating leases
$6.0M
Finance leases
$69M
The liability is the present value of the rent still to pay, at December 31, 2025. It is not counted in the ladder's debt. The filing
From the statutory to the effective tax rate, 2025
Dec 31, 2025Statutory rate
25.0%
Effective rate
-151.6%
The company paid -151.6% in tax on its profit, 176.6 points below the statutory rate it starts from (25.0%). Below, the reasons it gives.
Statutory rate
25.0%
Change in valuation allowance
-133.1 pts
Difference the filing does not itemize
-43.5 pts
Effective rate
-151.6%
One point is 1% of profit before tax. The lines are as the company states them in the notes to its annual report. The filing
Earnings quality
How the reported earnings were made, read from the filings. A description, not a score: our tests found no link between these measures and later share returns.
Where the change in earnings per share came from
Diluted earnings per share went from $0.04 in the fiscal year to Dec 31, 2024 to $2.07 in the year to Dec 31, 2025, a change of +$2.03.
Measured by size, 37.5% of the movement came from outside sales and operating margin: interest and other items, the tax rate, what went to others and the share count.
- +$0.12
- +$1.19
- -$0.03
- +$0.71
- +$0.04
Earnings per share is split as sales times operating margin, plus interest and other items, after tax, times the part that goes to the common shareholders, divided by the diluted share count. Each source's part is its average effect over every order in which the six can change, so the parts add up exactly to the change. From the annual reports; net income over the diluted count matches the earnings per share the company filed within 2%.
Receivables and inventory against sales are not shown: a figure it needs is missing from the company's structured filings.
The allowance for doubtful accounts is not shown: the company does not tag it in its structured filings.
The tax part is not shown: a figure it needs is missing from the company's structured filings.
A reading is called out when it is above the 90th percentile of the same reading across the S&P 500, or, for a fall, below the 10th, as measured on 9 November 2026. Each part uses only the company's own filings.
The full analysis
What do Aurinia Pharmaceuticals's filings show?
These are Aurinia Pharmaceuticals's figures from its filings. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
How much revenue did AUPH have in 2025?
Aurinia Pharmaceuticals had revenue of $283M and net income of $287M in fiscal 2025, a net margin of 101.5%.
How much debt does AUPH have?
On December 31, 2025 Aurinia Pharmaceuticals had total assets of $752M, debt of – and shareholders' equity of $581M.
How much free cash flow does AUPH have?
In fiscal 2025 Aurinia Pharmaceuticals had cash from operations of $136M and spent $252.0K on capital expenditure, leaving $135M of free cash flow.
Where are the figures from?
From Aurinia Pharmaceuticals Inc's annual and quarterly reports to the SEC, read from the structured data (XBRL) it files itself.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.